drugset / Trial / NCT02141854
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.
Timeline
- Start
- 2014-06
- Primary completion
- 2015-09
- Completion
- 2015-09
Publications
- Sher LD, Yiu G, Sakov A, Liu S, Caracta CF. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma. Allergy Asthma Proc. 2017 Sep 21;38(5):343-353. doi: 10.2500/aap.2017.38.4069. Epub 2017 Jun 21.
- Miller DS, Yiu G, Hellriegel ET, Steinfeld J. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016 Jul;37(4):291-301. doi: 10.2500/aap.2016.37.3963. Epub 2016 May 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone propionate | Other / unclassified | 100 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 200 ug | Inhaled |
| Background | salmeterol xinafoate | Unknown | 12.5 ug | Inhaled |
| Background | Salbutamol | Unknown | — | Inhaled |
| Background | salmeterol xinafoate | Unknown | — | Inhaled |